Conatus Pharmaceuticals

Conatus to Slash Staff, Consider Sale After NASH Trial Failures
Xconomy
Tue, 06/25/19 - 09:13 am
Conatus Pharmaceuticals
NASH
layoffs
emricasan
Conatus Pharma to explore options as liver disease drug fails trial
Yahoo/Reuters
Mon, 06/24/19 - 07:20 pm
Conatus Pharmaceuticals
clinical trials
NASH
emricasan
Novartis
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Xconomy
Thu, 04/5/18 - 11:57 pm
Conatus Pharmaceuticals
clinical trials
Novartis
emricasan
liver disease
hepatitis C
Novartis continues its blitz on NASH deals, grabbing an exclusive tie-up in race to develop cocktails
Endpoints
Thu, 05/4/17 - 08:02 pm
Novartis
NASH
Conatus Pharmaceuticals
Allergan
2 Attractive Small Biotech Stocks That Could Become Buyout Targets
Seeking Alpha
Wed, 09/23/15 - 09:55 pm
M&A
biotech
Conatus Pharmaceuticals
Dynavax
Amgen
Celgene
Gilead Sciences
4 New Big FDA Decisions Expected in September
24/7 Wall St
Sat, 09/5/15 - 11:01 am
FDA
Tetraphase
VTI208
Vital Therapies
Conatus Pharmaceuticals
Lexicon Pharmaceuticals
telotristat
Conatus: Emricasan's 4 Indications Present A Lucrative Opportunity In The Liver Disease Market
Seeking Alpha
Sat, 07/18/15 - 10:48 am
Conatus Pharmaceuticals
emricasan
liver disease
NASH
cirrhosis
After hep C cure, companies target next big liver disease market
Yahoo/Reuters
Sun, 11/9/14 - 09:46 am
hepatitis B
hepatitis
nonalcoholic steatohepatitis
Gilead
Galmed Pharmaceuticals
Raptor Pharmaceuticals
Conatus Pharmaceuticals
What Is Next For The Hepatitis C Space?
Seeking Alpha
Fri, 06/13/14 - 11:05 am
hepatitis C
Conatus Pharmaceuticals
Gilead Sciences
Merck
Idenix
Intercept’s Fibrosis Success Gives Galectin High Hope
Wall St Cheat Sheet
Tue, 01/28/14 - 12:17 pm
Intercept Pharma
Galectin
Conatus Pharmaceuticals
OCA
Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside
Wall St 24/7
Mon, 01/27/14 - 09:21 am
Avanir
BioDelivery Sciences
Conatus Pharmaceuticals
Geron
Halozyme
Neurocrine
Orexigen
Liver Drug Race: Intercept Pharma Vs. Rivals
Seeking Alpha
Mon, 01/27/14 - 08:21 am
Intercept Pharma
liver disease
OCA
Conatus Pharmaceuticals
Gilead Sciences
Galectin
NASH
non-alcoholic fatty liver disease
Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting(R)
Yahoo/Globe Newswire
Sat, 11/2/13 - 11:31 am
emricasan
Conatus Pharmaceuticals
Does Conatus Pharmaceuticals Have A Winner With Emricasan?
Seeking Alpha
Thu, 09/26/13 - 08:12 am
Conatus Pharmaceuticals
emricasan
Gilead
Merck
Pfizer
liver disease
Sunesis
apoptosis